Randomized, Open-label, phase3 Trial Comparing Amrubicin Combined With Cisplatin Versus Etoposide-Cisplatin as First-line Treatment in Patients With Extensive Disease SCLC.
Phase of Trial: Phase III
Latest Information Update: 09 Apr 2016
At a glance
- Drugs Amrubicin (Primary) ; Cisplatin; Etoposide
- Indications Small cell lung cancer
- Focus Registrational; Therapeutic Use
- 04 Jun 2013 Preliminary results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
- 05 Sep 2012 Data from this trial was used in support of an imported drug registration application cancer in China for amrubicin to the State Food and Drug Administration for the treatment of small cell lung cancer on 21 August 2012.
- 05 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History